HSA
HRTX icon

HBK Sorce Advisory’s Heron Therapeutics HRTX Stock Holding History

HBK Sorce Advisory’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$12.6K – 678
2025
Q4 		$12.6K Hold
10,000
– – ﹤0.01% 625
2025
Q3 		$13.5K Buy
+10,000
New +$15.9K ﹤0.01% 621

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

HBK Sorce Advisory's HRTX Position: Q1 2026 in Review

HBK Sorce Advisory sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 10,000 shares — an estimated $12.6K sold.

HBK Sorce Advisory first reported a position in HRTX in Q3 2025 and held it in 2 quarters. The position peaked at $13.5K in Q3 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • HBK Sorce Advisory reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HBK Sorce Advisory sold 10,000 Heron Therapeutics shares in Q1 2026, an estimated $12.6K.
  • HBK Sorce Advisory first reported a position in Heron Therapeutics in Q3 2025 and held it in 2 quarters.
  • HBK Sorce Advisory's Heron Therapeutics position peaked at $13.5K in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on HBK Sorce Advisory's 13F filing for Q1 2026, filed 11 May 2026.